MarketPeel
Insider Trading Intelligence
BD

Blaine Davis

RNAC
CHIEF FINANCIAL OFFICER · CARTESIAN THERAPEUTICS, INC. · CIK 0001802188
FILING MIX · LIFETIME69%/31%
BUYS
11
SELLS
5
TOTAL VALUE
$1.23M
COMPANIES
2
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
141,882
AVG SELL PX
$0.95
TRADE KIND
SHOWING 16 / 16
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
4 backtested trades · 8 horizons · 5 pending
Forward-return performance of every backtestable P/S trade by Blaine Davis, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d4+50.00%+3.21%-0.84%+4.05%+4.10%
14d4+25.00%+12.94%+0.40%+12.54%+12.41%
30d4+50.00%+10.98%+1.19%+9.79%+12.66%
60d4+50.00%+9.22%-0.26%+9.48%+8.03%
90d4+100.00%-8.62%-4.25%-4.37%-12.16%
180d4(1 pending)+100.00%-22.70%+10.08%-32.78%-37.65%
1y4(1 pending)+66.67%-60.24%+22.25%-82.48%-76.62%
2y4(3 pending)+0.00%-79.79%+16.64%-96.43%-96.43%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
RNAC · 121,220 shares · as of Jan 6, 2026
0777,5001,555,0002,332,5003,110,000202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 11 buys / 5 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
RNAC
CARTESIAN THERAPEUTICS, INC.
SALE
Chief Financial Officer
10,591$6.82$72.2K121,220Jan 6, 2026Jan 8, 2026View →
RNAC
CARTESIAN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
37,000131,811Jan 2, 2026Jan 6, 2026View →
RNAC
CARTESIAN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
109,000109,000Jan 2, 2026Jan 6, 2026View →
RNAC
CARTESIAN THERAPEUTICS, INC.
SALE
Chief Financial Officer
4,028$16.83$67.8K94,811Jan 6, 2025Jan 7, 2025View →
RNAC
CARTESIAN THERAPEUTICS, INC.
SALE
Chief Financial Officer
3,961$16.72$66.2K98,839Jan 3, 2025Jan 7, 2025View →
RNAC
CARTESIAN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
22,000102,800Jan 2, 2025Jan 6, 2025View →
RNAC
CARTESIAN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
64,60064,600Jan 2, 2025Jan 6, 2025View →
RNAC
CARTESIAN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,424,0002,424,000Jan 2, 2024Jan 4, 2024View →
RNAC
CARTESIAN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
3,110,0003,110,000Jan 2, 2024Jan 4, 2024View →
RNAC
CARTESIAN THERAPEUTICS, INC.
SALE
Chief Financial Officer
1,250,000$0.79$987.5K0Nov 13, 2023Nov 15, 2023View →
TARA
PROTARA THERAPEUTICS, INC.
SALE
Chief Financial Officer
5,081$3.13$15.9K20,662Jul 15, 2022Jul 19, 2022View →
TARA
PROTARA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
14,10015,581Jan 3, 2022Jan 5, 2022View →
TARA
PROTARA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
84,80084,800Jan 3, 2022Jan 5, 2022View →
TARA
PROTARA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
75,00075,000Jan 19, 2021Jan 21, 2021View →
TARA
PROTARA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
1,481$16.91$25.0K1,481Sep 22, 2020Sep 22, 2020View →
TARA
PROTARA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
94,00094,000Feb 11, 2020Feb 11, 2020View →
Other insiders · RNAC
Loading peer insiders…
About this filer
CIK 0001802188
ROLE
Chief Financial Officer
PRIMARY
RNAC
COMPANIES
2
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001802188DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback